drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR NK cell therapy)
drug_description
Investigational allogeneic CD19-directed CAR NK cell therapy (adoptive cell immunotherapy) engineered to recognize CD19 and trigger NK cell cytotoxicity to deplete CD19+ B cells.
nci_thesaurus_concept_id
C181804
nci_thesaurus_preferred_term
Allogeneic CD19-OX40-CD3zeta-CAR-mbIL-15-expressing Natural Killer Cells NKX019
nci_thesaurus_definition
A preparation of off-the-shelf (OTS), allogeneic and ex vivo expanded natural killer cells (NKs) that are engineered to express membrane-bound IL-15 (mbIL15) and a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 that is coupled to the co-stimulatory domain of OX40 (CD134), and to the zeta chain of the TCR/CD3 complex (CD3-zeta; CD3zeta), with potential immunomodulating and antineoplastic activities. Upon administration of allogeneic CD19-OX40-CD3zeta-CAR-mbIL-15-expressing NK cells NKX019, these cells specifically target and bind to tumor cells expressing CD19. This induces secretion of pro-inflammatory cytokines and results in the lysis of CD19-expressing tumor cells. IL-15 is a pro-survival cytokine that potentiates the immune response against tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.
drug_category
CAR NK
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Off‑the‑shelf allogeneic natural killer cells engineered with a CD19‑specific chimeric antigen receptor containing OX40 and CD3ζ signaling domains and membrane‑bound IL‑15 to enhance survival/persistence. Upon binding CD19 on B cells, the CAR NK cells degranulate (perforin/granzyme) and secrete pro‑inflammatory cytokines, leading to targeted lysis and depletion of CD19+ B cells.
drug_name
NKX019
nct_id_drug_ref
NCT06733935